Development and validation of an UPLC-ESI-MS/MS method for determination of dehydroevodiamine, limonin, evodiamine, and rutaecarpine in Evodiae Fructus
- PMID: 25210328
- PMCID: PMC4159934
- DOI: 10.4103/0973-1296.137381
Development and validation of an UPLC-ESI-MS/MS method for determination of dehydroevodiamine, limonin, evodiamine, and rutaecarpine in Evodiae Fructus
Abstract
Objective: Evodiae Fructus (EF), one of the most widely used traditional Chinese medicines, mainly consists of alkaloids, is widely used for the treatments of headache and gastrointestinal disorders. In this study, a sensitive and reliable UPLC-ESI-MS/MS method was developed for qualitative determination of dehydroevodiamine, limonin, evodiamine, and rutaecarpine.
Materials and methods: Chromatographic separations were accomplished on a Phenomenex Kinetex XB-C18 column (2.1 × 150 mm, 1.7 μm) by using a gradient elution profile with a mobile phase consisting of 0.5% formic acid in water (A) and acetonitrile (B). Detection was performed using multiple reactions monitoring mode under ESI in the positive ion mode.
Results: The results showed good linearity over the investigated concentration ranges (R (2)>0.9900) for the analytes. The limit of quantitations (LOQs) were 6.88 ng/mL for dehydroevodiamine, 18.6 ng/mL for limonin, 6.24 ng/mL for evodiamine, and 2.56 ng/mL for rutaecarpine, respectively. Intraday and interday precisions (relative standard deviations, %) were <5% and accuracies ranged from 92% to 106%.
Conclusion: The validated method was successfully applied to assay the contents of the four compounds in EF samples from different regions, with which just 10 min was needed to analyze each sample.
Keywords: Evodiae Fructus; Quantitative determination; UPLC-ESI-MS/MS.
Conflict of interest statement
Figures





Similar articles
-
The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: A review.Front Pharmacol. 2022 Nov 18;13:1040154. doi: 10.3389/fphar.2022.1040154. eCollection 2022. Front Pharmacol. 2022. PMID: 36467053 Free PMC article. Review.
-
[Qualitative and quantitative analysis of Evodiae Fructus based on the UPLC technology].Zhongguo Zhong Yao Za Zhi. 2017 Oct;42(20):3945-3956. doi: 10.19540/j.cnki.cjcmm.20170807.007. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 29243432 Chinese.
-
A sensitive liquid chromatographic-mass spectrometric method for simultaneous determination of dehydroevodiamine and limonin from Evodia rutaecarpa in rat plasma.Anal Bioanal Chem. 2011 Jul;401(1):289-96. doi: 10.1007/s00216-011-5072-6. Epub 2011 May 14. Anal Bioanal Chem. 2011. PMID: 21573727
-
Chiral high-performance liquid chromatographic separation of evodiamine enantiomers and rutaecarpine, isolated from Evodiae fructus.J Pharm Biomed Anal. 2013 Jul-Aug;81-82:151-9. doi: 10.1016/j.jpba.2013.04.018. Epub 2013 Apr 22. J Pharm Biomed Anal. 2013. PMID: 23666252
-
Analysis of Evodiae Fructus by capillary electrochromatography-mass spectrometry with methyl-vinylimidazole functionalized organic polymer monolilth as stationary phases.J Chromatogr A. 2019 Sep 27;1602:474-480. doi: 10.1016/j.chroma.2019.06.011. Epub 2019 Jun 5. J Chromatogr A. 2019. PMID: 31202495
Cited by
-
Evodiae Fructus extract suppresses inflammatory response in HaCaT cells and improves house dust mite-induced atopic dermatitis in NC/Nga mice.Sci Rep. 2024 Jan 4;14(1):472. doi: 10.1038/s41598-023-50257-3. Sci Rep. 2024. PMID: 38172219 Free PMC article.
-
Limonin: A Review of Its Pharmacology, Toxicity, and Pharmacokinetics.Molecules. 2019 Oct 12;24(20):3679. doi: 10.3390/molecules24203679. Molecules. 2019. PMID: 31614806 Free PMC article. Review.
-
The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: A review.Front Pharmacol. 2022 Nov 18;13:1040154. doi: 10.3389/fphar.2022.1040154. eCollection 2022. Front Pharmacol. 2022. PMID: 36467053 Free PMC article. Review.
-
Analysis of E. rutaecarpa Alkaloids Constituents In Vitro and In Vivo by UPLC-Q-TOF-MS Combined with Diagnostic Fragment.J Anal Methods Chem. 2016;2016:4218967. doi: 10.1155/2016/4218967. Epub 2016 Jun 30. J Anal Methods Chem. 2016. PMID: 27446630 Free PMC article.
References
-
- State Pharmacopoeia Committee. Beijing: China Medical Science Press; 2010. Chinese Pharmacopoeia [S]
-
- Moon TC, Murakami M, Kudo I, Son KH, Kim HP, Kang SS, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999;48:621–5. - PubMed
-
- Yarosh DB, Galvin JW, Nay SL, Pena AV, Canning MT, Brown DA. Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine. J Dermatol Sci. 2006;42:13–21. - PubMed
-
- Matsuda H, Wu JX, Tanaka T, Iinuma M, Kubo M. Antinociceptive activities of 70% methanol extract of evodiae fructus (fruit of Evodia rutaecarpa var. bodinieri) and its alkaloidal components. Biol Pharm Bull. 1997;20:243–8. - PubMed
-
- Kobayashi Y. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 2003;69:425–8. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous